Patent intelligence · US
US 8658787
Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
Patent details — US 8658787
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 25, 2014
- Expiration
- Feb 20, 2034
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Claims
- 44
- CPC classes
- A61K, A61K31/732, A61K31/736, A61K45/06
Quick answer
US 8658787 (Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Feb 25, 2014. Expires Feb 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GALECTIN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 44
- CPC classes
- A61K, A61K31/732, A61K31/736, A61K45/06, A61P, A61P1/16
More from GALECTIN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12377102
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11583530
Compounds for the prevention and treatment of medical disorders and uses thereof
granted -
US 11576924
Compounds for the prevention and treatment of diseases and the use thereof
granted -
US 11413303
Methods for treatment of arthritis
granted -
US 10799525
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 10744154
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
granted -
US 10420793
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 9974802
Composition of novel carbohydrate drug for treatment of human diseases
granted
Related coverage
Frequently asked questions
What is US patent 8658787?
US 8658787 (Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) is held by GALECTIN THERAPEUTICS, INC.. Status: granted. Granted Feb 25, 2014. Expires Feb 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8658787?
GALECTIN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 20 pharmaceutical patents for this assignee.
When does US 8658787 expire?
Our index shows an expiration date of Feb 20, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.